News | May 22, 2026
OncoSil secures TGA approval for pancreatic cancer device
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Subscribe To Our Newsletter & Stay Updated
